Skip to content

Efficacy and Safety of Botulinum Toxin Type A Combining Triamcinolone and 5-Fluorouracil in the Treatment of Hypertrophic Scars

Botulinum Toxin Type A Combining Triamcinolone and 5-Fluorouracil in the Treatment of Hypertrophic Scars: A Prospective, Open clinical, Randomized Controlled Trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044129
Enrollment
Unknown
Registered
2021-03-11
Start date
2021-03-11
Completion date
Unknown
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertrophic scar

Interventions

Sponsors

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients with age more than 18 years; 2.Length of scar is no less than 10 mm; 3.Initial Vancouver Scar Scale score is no less than 10; 4.Patients who can receive a 6-month follow up.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or planning to be pregnant within six months or who are breast-feeding; 2. Abnormal complete blood count or abnormal renal and liver function; 3. Patients had either Botulinum toxin type Atriamcinolone or 5- fluorouracil intralesional before in the same scar within 6 months; 4. Allergic to botulinum toxin type A, triamcinolone, 5-fluorouracil or lidocaine; 5. Diabetes or other basic diseases; 6. Immunosuppression or other status not suitable for treatment.

Design outcomes

Primary

MeasureTime frame
Vancouver Scar Scale;

Secondary

MeasureTime frame
visual analogue scale;length of scar;width of scar;

Countries

China

Contacts

Public ContactFei Liu

Shanghai 9th Peoples Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Plasticliu@hotmail.com+86 13817377740

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026